Sganga, Gabriele
Baguneid, Mohamed
Dohmen, Pascal
Giamarellos-Bourboulis, Evangelos J.
Romanini, Emilio
Vozikis, Athanassios
Eckmann, Christian
Funding for this research was provided by:
Angelini Pharma
Università Cattolica del Sacro Cuore
Article History
Received: 31 December 2020
Accepted: 11 March 2021
First Online: 26 March 2021
Declarations
:
: Gabriele Sganga, Mohamed Baguneid, Pascal Dohmen, Emilio Romanini and Athanassios Vozikis declare no conflicts of interest. E.J. Giamarellos-Bourboulis has received honoraria from AbbVie USA, Abbott CH, Biotest Germany, Brahms GmbH, InflaRx GmbH, MSD Greece, XBiotech Inc. and Angelini Italy; independent educational grants from AbbVie, Abbott, Astellas Pharma Europe, AxisShield, bioMérieux Inc, InflaRx GmbH, the Medicines Company and XBiotech Inc.; and funding from the FrameWork 7 program HemoSpec (granted to the National and Kapodistrian University of Athens), the Horizon2020 Marie-Curie Project European Sepsis Academy (granted to the National and Kapodistrian University of Athens), and the Horizon 2020 European Grant ImmunoSep (granted to the Hellenic Institute for the Study of Sepsis). Christian Eckmann received honoraria for lectures and advisory boards from Angelini, Correvio, Nabriva, Merck and Pfizer.
: “Not applicable”. Our manuscript does not report on, or involve the use of any animal or human data or tissue, and does not contain data from any individual person, so this section is not applicable to our submission.
: “Not applicable”. Our manuscript does not contain data from any individual person, so this section is not applicable to our submission.